ライフサイエンスコーパス: Fisher's exact test

1 d in 0.7% and 0.1%, respectively (P=0.002 by Fisher's exact test).

2 from 62 untreated patients (3%) (P = 0.007, Fisher's Exact test).

3 ters in the VRP-HA-vaccinated group (P<.001, Fisher's exact test).

4 ients with B- and T-ALL subtypes (P = 0.011, Fisher's exact test).

5 480 ethnically matched controls (p = 0.014, Fisher's exact test).

6 ted with neurocognitive deficit (P < 0.0025, Fisher's exact test).

7 s showing loss of one copy of PU.1 (P=0.001, Fisher's exact test).

8 ras mutations (codons, 12 and 13) (P=0.048), Fisher's exact test).

9 sponse to TNF inhibitor therapy (P < 0.01 by Fisher's exact test).

10 etween the two clusters was UGT1A1 (P=0.002; Fisher's exact test).

11 noma and at 1p, 3p, and 17p in SCC (P <0.05, Fisher's exact test).

12 with the ganciclovir implant alone (P=.023; Fisher's exact test).

13 s ratio, 10.23; 95% CI, 1.3 to 83.3; P=0.01, Fisher's exact test).

14 recipients of CVD 1208 (brief fever) (P=.02, Fisher's exact test).

15 and STAT3 activation was observed (P =.007, Fisher's exact test).

16 ompared with others (48 vs 33%; p = 0.028 by Fisher's exact test).

17 h none of the 16 control patients (p = .007, Fisher's exact test).

18 was correlated with that of DAPK (P = 0.04, Fisher's exact test).

19 ason 4-6 tumors (11 out of 20, 55%, P=0.032, Fisher's exact test).

20 at received grafts from HBV- donors (P<0.05, Fisher's exact test).

21 ssified volunteers and patients (P = 0.0022, Fisher's exact test).

22 compared with adenocarcinoma (22%; P = 0.03; Fisher's exact test).

23 n and an advanced pathologic stage (P=0.003, Fisher's exact test).

24 rsus 0 of 126 white patients (P < 0.0001, by Fisher's exact test).

25 bject without (p = 3.12 x 10(-3), two-tailed Fisher's exact test).

26 nd none of six in the SAAP-LR group (p <.05, Fisher's exact test).

27 fective for intense inflammation (P = 0.023, Fisher's exact test).

28 e of 11 of the unaffected patients (p=0.012, Fisher's exact test).

29 cation in their prior benign biopsy (P =.06, Fisher's exact test).

30 h 6 of 34 of those with UC >1 year (P = .04, Fisher's exact test).

31 ith other histological cell types (P = 0.01, Fisher's exact test).

32 ciated with alveolar histology (P = <0.0001, Fisher's exact test).

33 d to controls (14.6% versus 10.6%; P = 0.02, Fisher's exact test).

34 r anti-P (odds ratio [OR] 9.6, P < 10(-8) by Fisher's exact test).

35 imals died within 3 days of surgery (P =.02, Fisher's exact test).

36 tly adjacent to a CSF reservoir (P < 0.0001, Fisher's exact test).

37 ly associated with infant mortality (P=.035, Fisher's exact test).

38 (P = 0.041 and P = 0.0385, respectively, by Fisher's exact test).

39 id not develop secondary neoplasms (P =.008; Fisher's exact test).

40 ed a mutation in the paired serum (P = 0.01, Fisher's exact test).

41 se in measurable disease (P=.0369, two-sided Fisher's exact test).

42 CCR5/CCR5 homozygotes (29/88, 33%; P < .001, Fisher's exact test).

43 ls to 0.12 in Alzheimer's disease (P < 0.05, Fisher's exact test).

44 de the prostate fossa and pelvis (P = .0225, Fisher's exact test).

45 .8%) and in 10 with ETS (52.6%) (P = 0.0298, Fisher's exact test).

46 8%) and in two with ETS (10.5%) (P = 0.0005, Fisher's exact test).

47 y between OA cases and controls (P = 0.03 by Fisher's exact test).

48 ompared with 22% in the PLA group (P < .001, Fisher's exact test).

49 ETS (47.4%) and none with HTS (P = 0.0015), Fisher's exact test).

50 ts (81.3%) but in none with ETS (P < 0.0001, Fisher's exact test).

51 e 91 elevated ESR patients (81%) (P<0.02, by Fisher's exact test).

52 on rates decreased from 19% to 8% (P = .005, Fisher's exact test).

53 the TNFR5-G1,3-treated animals (p < 0.01 by Fisher's exact test).

54 /=1:10 in postimmunization sera (P = 0.0008, Fisher's exact test).

55 cts with CHDs (p = 3.30 x 10(-2), two-tailed Fisher's exact test).

56 red to the non-ischemic patients (P = 0.005, Fisher's exact test).

57 s experiencing progression to PCa (P = .014, Fisher's exact test).

58 n the fellow eyes only in 3 cases (p = 0.13, Fisher's exact test).

59 ters combined (1.6% versus 4.7%, P = 0.02 by Fisher's exact test).

60 cinomas were in the slow DT group (P<0.0002; Fisher's exact test).

61 fied in the same gene in controls (p = .023; Fisher's exact test).

62 cancers were in the slow DT group (P<0.0001; Fisher's exact test).

63 th no history of breast carcinoma (P = .007, Fisher's exact test).

64 %) platinum-sensitive recurrences (P = .003, Fisher's exact test).

65 .0% to 10.7%) primary carcinomas (P = .0003, Fisher's exact test).

66 and without linkage evidence (P=2x10(-17) by Fisher's exact test).

67 rm and 10.2% in the placebo arm (P = .768 by Fisher's exact test).

68 ive factor against alcoholism (P = 0.0038 by Fisher's exact tests).

69 olecular subtype ( P = .383), as assessed by Fisher's exact test.

70 mpared between HbA1c <6 and > or =6.1% using Fisher's exact test.

71 t-test, Mann-Whitney U test, chi-square, or Fisher's exact test.

72 d by Student's t test, chi-square tests, and Fisher's exact test.

73 and delivery were made by student t test or Fisher's exact test.

74 d to those for 554 healthy controls by using Fisher's exact test.

75 Categorical data were evaluated with Fisher's exact test.

76 HLA-DR allele frequencies among patients, by Fisher's exact test.

77 comparison of between-groups differences by Fisher's exact test.

78 Haplotype frequencies were compared using Fisher's exact test.

79 and genotype frequencies were compared using Fisher's exact test.

80 performed with Wilcoxon's rank sum test and Fisher's exact test.

81 e prevalence of mutations was compared using Fisher's exact test.

82 tween groups in proportions were assessed by Fisher's exact test.

83 3-month follow-up period was compared using Fisher's exact test.

84 col was assessed with the use of a one-sided Fisher's exact test.

85 tested for by using either the chi(2) or the Fisher's exact test.

86 analysed using Chi-square test or Univariate Fisher's exact test.

87 with the small-sample method (SSM) based on Fisher's exact test.

88 ll survival in each group was compared using Fisher's exact test.

89 HCV infection and HLA zygosity with 1-sided Fisher's exact tests.

90 aluation included Pearson chi-square and the Fisher's exact tests.

91 nction was compared using Kruskal-Wallis and Fisher's exact tests.

92 Frequencies were compared using chi(2) or Fisher's exact tests.

93 haracteristics were examined with chi(2) and Fisher's exact tests.

94 those without affected male relatives, using Fisher's exact tests.

95 lications was performed using chi-square and Fisher's exact tests.

96 eived recommended care was compared by using Fisher's exact tests.

97 ites were compared by race and by sex, using Fisher's exact tests.

98 linear regression, 2-sample t, log-rank, and Fisher's exact tests.

99 ithout PTLD (specificity = 100%) (P < 0.001 [Fisher's exact test]).

100 the distribution of subtypes was not random (Fisher's exact test 0.13; P>.05).

101 superior effect of SHUTi versus HealthWatch (Fisher's exact test=0.52; p=0.32).

102 (P = .0002 for comparison to ILV 20 Gy < 3%, Fisher's exact test); 20% (four of 20) for an ILV 10 Gy

103 was significantly associated with c.8057G>A (Fisher's exact test, adjusted p value < 0.0001).

104 stasis) was significantly increased (P=0.04, Fisher's exact test), although there was no increase in

105 Chi-square and Fisher's exact test analysis compared vaccination and do

106 Fisher's Exact Test and a logistic regression model were

107 The chi2 or Fisher's Exact test and ANOVA with adjusted multiple com

108 For statistic analyses Mann-Whitney U-test, Fisher's exact test and binary logistic regression were

109 al rate-comparison methods, e.g. chi 2 test, Fisher's exact test and Binomial test.

110 l characteristics and perceived burden using Fisher's exact test and bivariate modified Poisson regre

111 were analyzed using contingency tables with Fisher's exact test and compared with mismatched antigen

112 isms (with P values obtained with the use of Fisher's exact test and logistic regression ranging from

113 In addition, Fisher's exact test and logistic regression were used to

114 The new approach is compared with Fisher's exact test and other relevant methods in a simu

115 Results were analyzed using Fisher's exact test and Pearson's chi-square test.

116 o commonly used gene set enrichment methods, Fisher's exact test and the binomial test implemented in

117 Patient variables were compared by Fisher's exact test and the Student's t test.

118 Fisher's exact test and Wilcoxon rank sum test were used

119 ps between both arms were compared using the Fisher's exact test and Wilcoxon Rank Sum test.

120 e donors (13/32 vs. 6/41 responders; P=.016, Fisher's exact test) and fewer HLA-DQB1*0603-9/14-positi

121 ted with an increase in tumor size (P=0.009, Fisher's exact test) and lymph node involvement (P=0.04)

122 -, second-, and third-line treatment (chi(2)/Fisher's exact test) and median OS (Kaplan-Meier method/

123 ha and ER beta were node positive (P = 0.02; Fisher's exact test) and tended to be of higher grade.

124 tistically superior to the EIA (P, <0.001 by Fisher's exact test) and to the GDH-EIA-CCCN algorithm (

125 versus GAS-positive RA patients [n = 0], by Fisher's exact test), and 2 were also positive for GBS.

126 tein-derivative-negative (PPD-) (P < 0.0001, Fisher's exact test), and 7/8 PPD-positive (PPD+) subjec

127 okers without a history of cancer (P = 0.04, Fisher's exact test), and methylation of DAPK was detect

128 01, P < 0.0001, and P = 0.004, respectively, Fisher's exact test), and the sensitivity of GDH algorit

129 the tamoxifen-sensitive group (P = 0.001 by Fisher's exact test), and, consistent with previous find

130 to approaches such as Pearson's chi square, Fisher's exact test, and a test based on Cressie and Rea

131 Chi-square analysis, Fisher's exact test, and multivariable logistic regressi

132 analyzed by using the chi-square test or the Fisher's exact test, and p < .05 was considered signific

133 Fisher's exact tests, and multivariable logistic regress

134 henotype categories of susceptibility, using Fisher's exact test applied to 6,128 markers in publical

135 l probability with the tail probability from Fisher's exact test applied to the actual haplotype data

136 mosomal sites 8p, 9p, 11q, and 13q (P >0.05, Fisher's exact test) are targeted at the early stages, w

137 s versus 0 of 16 control patients (P< .0001, Fisher's exact test) at a median of 32 weeks (range, 17-

138 expected by simple addition alone (P <0.05, Fisher's exact test) between cotinine (800 ng/ml) and 1)

139 l, we adjusted the null distribution for the Fisher's exact test by weighting the identification prob

140 Data analysis included Fisher's exact test, chi-square test, Student's t-test,

141 y significant associations, we performed (a) Fisher's exact test comparing genotypes at each locus in

142 Cotinine significantly (P <0.05, Fisher's exact test) enhanced the effects of cell-free e

143 Fisher's exact test examined the effect of diagnosis on

144 e these methods with each other and with the Fisher's exact test (FET) method.

145 rs within these intervals that display small Fisher's exact test (FET) probabilities is directly prop

146 ) leukemias carried the CYP3A4-V (P = 0.026; Fisher's Exact Test, FET).

147 Using Fisher's exact test for comparing the numbers of cases a

148 d freedom from were used for analysis as was Fisher's exact test for comparisons between groups.

149 ests, we provide the first implementation of Fisher's exact test for the genotypic cytonuclear disequ

150 ortion of 22q11.2 deletions found, using the Fisher's exact test for the independent case-control stu

151 ssment by each modality using chi-square and Fisher's Exact tests for univariable correlation and log

152 ng-spawner and Norwegian fjord stocks, using Fisher's exact test, FST and RST values.

153 dhood eczema (chi2 test: P = 2.12 x 10(-51); Fisher's exact test: heterozygote odds ratio (OR) = 7.44

154 t week 4 (38% vs. 13%, P=0.04 by a two-sided Fisher's exact test in the A5340 trial; and 80% vs. 13%,

155 ial; and 80% vs. 13%, P<0.001 by a two-sided Fisher's exact test in the NIH trial) but the difference

156 irwise LD was estimated using three methods: Fisher's exact test, index of association (IA) and Hedri

157 Statistical analysis (Fisher's exact test) indicated there was no significant

158 ined analysis (p = 2.68 x 10(-4), two-tailed Fisher's exact test), indicating that the SLC2A3 duplica

159 The Fisher's exact test is commonly used.

160 he data were analyzed using a combination of Fisher's exact test, logistic regression modeling, and m

161 We analyzed the results using Fisher's exact tests, logistic regression, and generaliz

162 hereas LOH at 1p, 5q, 17p, and 18q (P <0.05, Fisher's exact test) occur at the later stages of non-sm

163 ients: MTHF, 2 of 25 (8%); FA, 0 of 25 (0%); Fisher's exact test of between-groups difference, P=0.49

164 the C102 allele and the presence of visual (Fisher's exact test, one-tailed, P = 0.003) and auditory

165 led, P = 0.003) and auditory hallucinations (Fisher's exact test, one-tailed, P = 0.004) and between

166 ome and histamine levels were assessed using Fisher's exact test or Student's t-test.

167 lar compartment and prognostic factors using Fisher's Exact test or with patient survival over 20 yea

168 ar groups, respectively (IPV versus control: Fisher's exact test P < 0.001).

169 ngly associated with induction of apoptosis (Fisher's exact test P < 0.015) and reduction in urine ba

170 significantly reduced at 1, 12 and 52 weeks (Fisher's Exact Test p = 0.018, chi(2) = 5.1 p = 0.02 and

171 red with single-vision spectacles (one-sided Fisher's exact test P = 0.025).

172 ne of 12 patients with plaque-stage disease (Fisher's exact test p = 0.027).

173 on in idiopathic focal childhood epilepsies (Fisher's exact test P = 2.1 x 10(-4)).

174 rols (5/393 cases versus 32/65,046 controls; Fisher's exact test P = 2.83 x 10(-6), odds ratio = 26.2

175 red with secondary groups (11/49 vs 211/230: Fisher's exact test p<0.0001).

176 y of GCH1 variants was significantly higher (Fisher's exact test P-value 0.0001) in cases (10/1318 =

177 mpared with three (9%) of the 32 on placebo (Fisher's exact test p=0.05).

178 locations involving CBFA2 was significant by Fisher's exact test (P < .003).

179 evated PET score (i.e., PET score > 1) using Fisher's exact test (P < 0.05).

180 n all tumor types by both the chi(2) and the Fisher's exact tests (P < 0.0001 for both tests).

181 ases in volunteers receiving active product (Fisher's exact test, P < .0017).

182 with sun-protected sites (1.1%, one of 90) (Fisher's exact test, p < 0.0001).

183 the Fanconi anemia protein FANCD2 (corrected Fisher's exact test, P < 0.0007).

184 ed axillary lymph nodes, a high concordance (Fisher's exact test, P < 0.001) was seen between PCR det

185 cancer as compared with the benign prostate (Fisher's exact test, P < 0.001).

186 compared with nonresponders (11 of 20, 55%; Fisher's exact test, P < 0.029).

187 were 9.9% for FOLFOX4 versus 0% for LV5FU2 (Fisher's exact test, P <.0001).

188 common c.2439C/C (89% vs 40%, respectively; Fisher's exact test, P = 0.01).

189 nce in wild-type littermates (16 of 19; 84%; Fisher's exact test, P = 0.012).

190 st to 0.6% (2 of 327) in 327 unaffected men (Fisher's exact test, P = 0.018), with an odds ratio (OR)

191 ithout sporadic medullary thyroid carcinoma (Fisher's exact test, P = 0.03).

192 eased in FTAAD compared with STAAD patients (Fisher's exact test, p = 0.03).

193 ong patients with type II diabetes mellitus (Fisher's exact test, p = 0.035).

194 mary tumors without distant metastasis (5%) (Fisher's exact test, P = 0.05; chi(2) = 0.04).

195 ard reduction in the incidence of infection (Fisher's exact test, p =.07; odds ratio,.76) in the gown

196 s, in which aneuploidy was more common (69%; Fisher's exact test, P=0.0033).

197 nt compared with 38% in the wait-list group (Fisher's exact test, P=0.01).

198 id not correlate with absent pRB expression (Fisher's exact test, P=0.375).

199 interview modes (12.5% ACASI vs. 10.9% FTFI; Fisher's exact test: P = 0.72).

200 operfusion of right superior temporal gyrus (Fisher's exact test; p < 0.0001), whereas left "egocentr

201 g > Rev > Pol > Nef > Vif > Tat > Env > Vpu (Fisher's exact test; P < or = 0.0009 for each comparison

202 LA-DQB1*0301-negative patients (52% vs. 88%; Fisher's Exact Test; P = 0.007).

203 bination with pmurGMCSF gave 40% protection (Fisher's exact test; P = 0.03, vaccinated versus control

204 n and HPV infection were mutually exclusive (Fisher's exact test; P = 0.0357): two HPV-negative cervi

205 n (64 of 67 ears with elevated protein; 96%)(Fisher's exact test; P<0.0001) in both normal and hearin

206 hearing loss (32/34 hearing loss ears; 94%)(Fisher's exact test; P= .005).

207 gnosis), we found a significant (P < 0.0001, Fisher's exact test) reduction in the number of edematou

208 pite a serious limitation, a method based on Fisher's exact test remains one of the few plausible opt

209 ns were made by using two sample t tests and Fisher's exact tests, respectively.

210 onse and improvement in QoL were assessed by Fisher's exact test statistic.

211 In the Bloom syndrome trial, by Fisher's exact test, statistically significant associati

212 urg, Germany) was significantly (P = 0.0096, Fisher's exact test) superior to orally administered dru

213 orrelation T(IC), as well as to the power of Fisher's exact test T(FET) applied to discretized data.

214 ed an increased prevalence of Apa1 A (P=.03; Fisher's exact test), TaqI t (P=.04), and the At VDR hap

215 DPRP provides three methods: the Fisher's Exact Test, the Kolmogorov-Smirnov test and the

216 ple uses on bisulfite-seq with P-values from Fisher's exact test, tiled methylation probes using a li

217 We used Fisher's exact test to compare unadjusted attack rates a

218 acid or N-glycosylation motif, and performs Fisher's exact test to detect potential positive or nega

219 By applying Fisher's exact test to identify enriched KEGG pathways a

220 l form, can be viewed as a generalization of Fisher's exact test to ternary variables.

221 iled Mann Whitney U exact tests, chi(2), and Fisher's exact tests to analyse the data.

222 We used chi(2) and Fisher's exact tests to compare categorical variables an

223 We performed chi-square and Fisher's exact tests to compare the frequencies of obser

224 alysis of variance for change from baseline, Fisher's exact test (two-tailed) for categorical compari

225 ive for enterovirus D68 using the two-tailed Fisher's exact test, two-sample unpaired t test, and Man

226 contrasted with absence of disease (P=0.029, Fisher's exact test, two-sided, verified by permutation

227 hi-square testing for categorical variables (Fisher's exact test used for violations of Cochran's ass

228 One-tail Fisher's exact test was conducted on each cross validati

229 Fisher's exact test was done for each single-nucleotide

230 tudent's t-test analyses were performed, and Fisher's exact test was used as appropriate.

231 Fisher's exact test was used for categoric variables, an

232 Fisher's exact test was used for comparisons.

233 Fisher's exact test was used for the primary end point,

234 Fisher's exact test was used to compare differences betw

235 Fisher's exact test was used to compare incidence and se

236 The Fisher's exact test was used to compare patient groups.

237 Fisher's exact test was used to compare the proportion o

238 Fisher's exact test was used to screen for association w

239 Although no statistical difference (Fisher's exact test) was detected (P = 0.242) between th

240 and Neisseria lactamica (P < 0.002) (2-sided Fisher's exact test) was more likely in the smaller, mor

241 Kaplan-Meier analysis and Fisher's exact test were used for comparisons between gr

242 ), Bland-Altman plot, kappa statistics, and Fisher's exact test were used to assess intra- and inter

243 used for continuous variables and t-tests or Fisher's exact tests were used to compare treatment grou

244 Fisher's exact tests were used to compare, by frailty st

245 Pearson chi square analysis or Fisher's exact test, when appropriate, was used for univ

246 c effects on longevity were also analyzed by Fisher's exact test, which indicated a significant life-

247 h HTS (31.3%) and none with ETS (P = 0.0135, Fisher's exact test), while an aura with experiential co

248 tected, pairwise comparisons were made using Fisher's exact test with a Bonferroni adjustment.

249 henotypes and CISs are also identified using Fisher's exact test with multiple testing correction.

250 in vivo is strongly associated (P < 2e-16 by Fisher's exact test) with nucleosome-free chromatin.

251 Fisher's exact test, with correction for multiple compar

252 ignificance was determined by chi-square and Fisher's exact tests, with a false discovery rate correc